Pharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
Covid-19 may no longer be causing the worldwide chaos it had in the past couple of years, but that does not mean it has left the pharma industry’s list of targets. As the virus mutates, so the vaccine makers have adjusted their mega-selling products to maintain efficacy. The news has been mixed for some of the drugs approved to treat the disease, however.